Allergan receives US FDA approval for Restasis Multidose for chronic dry eye

Allergan Introduces RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%, a New Delivery System for the One and Only FDA Approved Treatment to Help Patients Produce More of Their Own Tears.

Allergan plc (NYSE: AGN) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%, a preservative-free, multi-dose bottle offering the same preservative-free formulation of RESTASIS since the launch in 2003. RESTASIS® is the one and only prescription treatment FDA approved to help patients with a type of Chronic Dry Eye make more of their own tears.

RESTASIS® helps increase your eyes’ natural ability to produce tears, which may be reduced by inflammation due to Chronic Dry Eye. RESTASIS® did not increase tear production in patients using anti-inflammatory eye drops or tear duct plugs.

“RESTASIS MULTIDOSE™ will be an important addition to the Allergan family of dry eye products, as it will enable healthcare providers to offer an additional option for those patients who may prefer their eye drops in a multi-dose bottle versus single-use vials,

RESTASIS MULTIDOSE™ is designed with a patented unidirectional valve and air filter technology that eliminates the need for a preservative. The new multi-dose bottle uses less plastic than a package of single-use vials and will be available for the same price.